Inbrija (levodopa)
- Region
- 🇪🇺 EU
- Active substance
- levodopa
- Company
- Merz Therapeutics GmbH
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- CHMP opinion
- Thu 25 Jul 2019
- EU approval
- Thu 19 Sep 2019
- Application
- EMEA/H/C/004786
- ATC
- N04BA01
- Official record
- www.ema.europa.eu
Indication
Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Hopledo Authorised · Zambon SpA
- 🇪🇺 Onerji Authorised · Tanabe Pharma GmbH
- 🇪🇺 Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) Authorised · Orion Corporation
- 🇪🇺 Levodopa/Carbidopa/Entacapone Orion Authorised · Orion Corporation
- 🇪🇺 Stalevo Authorised · Orion Corporation
- 🇪🇺 Numient Withdrawn · Amneal Pharma Europe Ltd
Follow Inbrija
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.